Cerevel Therapeutics Holdings, Inc.
CERE
Rangering i aksjer
#2811
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm... Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) in Phase 1b trials for schizophrenia. Another PAM, Darigabat, is being assessed in a Phase 2 proof-of-concept study for drug-resistant focal onset seizures in epilepsy, as well as in a Phase 1 trial for acute anxiety. For Parkinson's disease, Cerevel is advancing Tavapadon, a selective dopamine D1/D5 partial agonist, through Phase 3 clinical trials for both early and late stages of the condition. A related compound, CVL-871, also a selective dopamine D1/D5 partial agonist, is in Phase 2a trials for dementia-related apathy. The company's portfolio further includes CVL-936, a selective dopamine D3-preferring antagonist in Phase I for substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist targeting major depressive disorder and substance use disorder; and CVL-047, a selective PDE4 inhibitor also aimed at major depressive disorder and substance use disorder. Beyond individual compounds, Cerevel is actively developing an M4 agonist program for psychosis and related indications, alongside an LRRK2 inhibitor program designed to address the progression of Parkinson's disease. Founded in 2018, Cerevel Therapeutics is headquartered in Cambridge, Massachusetts.
Aksjekurs
$44.96
Sist synkronisert: 2024-08-01
Markedsverdi
$6.67B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Cerevel Therapeutics Holdings, Inc. (CERE)
Kategori
Healthcare
P/E-forhold for Cerevel Therapeutics Holdings, Inc. (CERE)
P/E-forhold per October 2026 TTM: -16.84
Ifølge Cerevel Therapeutics Holdings, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) -16.84. Ved slutten av 2022 hadde selskapet en P/E på -13.57.
P/E-forholdshistorikk for Cerevel Therapeutics Holdings, Inc. fra 2012 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | -16.84 | 6.11% |
| 2023 | -15.87 | 16.96% |
| 2022 | -13.57 | -31.81% |
| 2021 | -19.91 | 54.55% |
| 2020 | -12.88 | 9.30% |
| 2019 | -11.78 | 549.47% |
| 2018 | -1.81 | -69.85% |
| 2015 | -6.02 | 4.14% |
| 2014 | -5.78 | 10.88% |
| 2013 | -5.21 | -9.54% |
| 2012 | -5.76 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 28.78 | -270.92% |
US
|
|
| -28.36 | 68.41% |
US
|
|
| -24.57 | 45.89% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -280.12% |
NL
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.